Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPISODE: Sucroferric oxyhydroxide vs lanthanum carbonate phosphate control in dialysis patients
jRCTs051180048Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of iron sucrose in hyperphosphatemia, end-stage kidney disease (ESKD) and Coronary artery calcification (CAC) (4 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: rate of change in CACS. Started Feb 2017; status: completed.
02
Drugs
iron sucrose
03
Conditions
hyperphosphatemiaend-stage kidney disease (ESKD)Coronary artery calcification (CAC)
Beyond the preview
Go deeper on jRCTs051180048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180048.